Anthera Pharmaceuticals, Inc. (ANTH) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ANTH representa a Anthera Pharmaceuticals, Inc., una empresa del sector Healthcare con un precio de $ (capitalización de mercado 0). Calificado con 41/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 15 mar 2026Anthera Pharmaceuticals, Inc. (ANTH) Resumen de Asistencia Médica y Tuberías
Anthera Pharmaceuticals, Inc. operates in the biotechnology sector, focusing on developing therapies for unmet medical needs. Their pipeline features Sollpura, a non-porcine pancreatic enzyme replacement therapy, and Blisibimod, targeting autoimmune diseases. The company navigates the competitive landscape of biopharmaceutical development with licensing agreements to bolster its portfolio.
Tesis de Inversión
Anthera Pharmaceuticals, Inc. presents a high-risk, high-reward investment profile within the biotechnology sector. The company's value hinges on the successful completion of clinical trials for Sollpura and Blisibimod. Positive Phase III results for Sollpura could drive significant market capitalization growth, addressing the unmet need for non-porcine pancreatic enzyme replacement therapy. However, the company's OTC listing and negative beta of -123.12 indicate substantial volatility and speculative trading. The lack of current revenue and reliance on future drug approvals create significant financial risk. Investors should closely monitor clinical trial outcomes and regulatory milestones to assess the potential for long-term value creation. The company's success is contingent on navigating the complex regulatory landscape and securing commercial partnerships.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Sollpura is in Phase III clinical trial for exocrine pancreatic insufficiency, representing a potential near-term value driver.
- Blisibimod is in Phase II clinical trial for B-cell mediated autoimmune diseases, indicating a longer-term growth opportunity.
- The company has license agreements with Amgen, Inc., and Eli Lilly and Company, providing potential revenue streams and validation of its technology.
- Anthera Pharmaceuticals, Inc. operates with a small team of 21 employees, suggesting a lean operational structure.
- The company's stock trades on the OTC market, indicating higher risk and volatility compared to major exchange listings.
Competidores y Pares
Fortalezas
- Innovative pipeline of drug candidates targeting unmet medical needs.
- Strategic partnerships with major pharmaceutical companies.
- Potential for orphan drug designation for certain therapies.
- Lean operational structure with a small team of employees.
Debilidades
- Limited financial resources and reliance on external funding.
- High risk of clinical trial failures and regulatory setbacks.
- Lack of established revenue streams and commercial infrastructure.
- OTC market listing indicating higher risk and volatility.
Catalizadores
- Upcoming: Results from Phase III clinical trial of Sollpura for exocrine pancreatic insufficiency.
- Upcoming: Data readout from Phase II clinical trial of Blisibimod for B-cell mediated autoimmune diseases.
- Ongoing: Potential for new licensing agreements with pharmaceutical companies.
- Ongoing: Regulatory milestones and potential FDA approval for Sollpura.
- Ongoing: Progress in expanding the company's pipeline through research and development.
Riesgos
- Potential: Failure of clinical trials for Sollpura or Blisibimod.
- Potential: Regulatory setbacks and delays in drug approval process.
- Ongoing: Competition from established pharmaceutical companies and emerging biotechs.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: OTC market listing indicating higher risk and volatility.
Oportunidades de crecimiento
- Expansion into New Therapeutic Areas: Anthera could leverage its expertise in drug development to expand into new therapeutic areas with unmet medical needs, such as rare diseases or oncology. This diversification could reduce the company's reliance on its current pipeline and create new revenue streams. The market for rare disease therapies is projected to reach $258 billion by 2030, offering significant growth potential.
- Geographic Expansion: Anthera could expand its commercial operations into new geographic markets, particularly in Asia and Europe, where there is a growing demand for advanced therapies. This expansion could increase the company's revenue and market share. The global pharmaceutical market is expected to reach $1.5 trillion by 2026, with emerging markets driving much of the growth.
- Strategic Partnerships and Acquisitions: Anthera could pursue strategic partnerships or acquisitions to expand its pipeline, access new technologies, or strengthen its market position. This could accelerate the company's growth and create synergies. The biotechnology industry is characterized by frequent mergers and acquisitions, with companies seeking to consolidate their market share and expand their capabilities.
- Orphan Drug Designation: Anthera can pursue orphan drug designation for its therapies targeting rare diseases. This designation provides incentives such as market exclusivity, tax credits, and reduced regulatory fees, enhancing the commercial viability of these products. The orphan drug market is growing rapidly, driven by increasing awareness of rare diseases and the development of new therapies.
- Advancements in Drug Delivery Technologies: Anthera can invest in innovative drug delivery technologies to improve the efficacy and patient compliance of its therapies. This could create a competitive advantage and increase the market potential of its products. The drug delivery market is expected to reach $240 billion by 2028, driven by the development of new and improved delivery systems.
Oportunidades
- Expansion into new therapeutic areas and geographic markets.
- Strategic acquisitions or licensing agreements to expand the pipeline.
- Advancements in drug delivery technologies to improve efficacy.
- Growing demand for therapies targeting rare diseases and autoimmune disorders.
Amenazas
- Competition from established pharmaceutical companies and emerging biotechs.
- Changes in regulatory policies and reimbursement models.
- Product liability claims and intellectual property disputes.
- Economic downturns and market volatility affecting funding availability.
Ventajas competitivas
- Patented drug formulations and delivery systems.
- Clinical trial data demonstrating efficacy and safety.
- Regulatory exclusivity for approved therapies.
- Established partnerships with major pharmaceutical companies.
Acerca de ANTH
Founded in 2004 and based in Houston, Texas, Anthera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative medicines for patients with unmet medical needs. The company's primary focus is on addressing diseases with limited or inadequate treatment options, striving to improve patient outcomes and quality of life. Anthera's lead product candidates include Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy currently in Phase III clinical trials for the treatment of exocrine pancreatic insufficiency (EPI). EPI is a condition where the pancreas does not produce enough enzymes to digest food properly. Additionally, Anthera is developing Blisibimod, a drug in Phase II clinical trials for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy (IgA nephropathy), a kidney disease. Anthera has established strategic collaborations through license agreements with major pharmaceutical companies like Amgen, Inc., and Eli Lilly and Company, enhancing its research and development capabilities and expanding its therapeutic pipeline. The company's commitment to innovation and patient-centric drug development positions it within the competitive biotechnology landscape.
Qué hacen
- Develops Sollpura, a non-porcine pancreatic enzyme replacement therapy.
- Conducts Phase III clinical trials for Sollpura to treat exocrine pancreatic insufficiency.
- Develops Blisibimod for B-cell mediated autoimmune diseases.
- Conducts Phase II clinical trials for Blisibimod to treat IgA nephropathy.
- Establishes license agreements with pharmaceutical companies like Amgen and Eli Lilly.
- Focuses on addressing unmet medical needs through innovative drug development.
- Aims to improve patient outcomes and quality of life through targeted therapies.
Modelo de Negocio
- Develops and patents novel pharmaceutical products.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Out-licenses or commercializes approved therapies.
Contexto de la Industria
Anthera Pharmaceuticals, Inc. operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation, with companies constantly seeking to develop novel treatments for unmet medical needs. Anthera's focus on exocrine pancreatic insufficiency and autoimmune diseases positions it within specific niches of the broader pharmaceutical market. Competitors include companies developing similar therapies, as well as established pharmaceutical giants. The company's success depends on its ability to navigate the regulatory landscape, secure funding, and effectively commercialize its products.
Clientes Clave
- Patients with exocrine pancreatic insufficiency (EPI).
- Patients with B-cell mediated autoimmune diseases, including IgA nephropathy.
- Healthcare providers who prescribe and administer Anthera's therapies.
- Pharmaceutical companies that partner with Anthera through licensing agreements.
Finanzas
Gráfico e información
Precio de la acción de Anthera Pharmaceuticals, Inc. (ANTH): Price data unavailable
Últimas noticias
-
Anthera Pharmaceuticals (OTCMKTS:ANTH) Stock Passes Above Two Hundred Day Moving Average – What’s Next?
defenseworld.net · 21 feb 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 mar 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para ANTH.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para ANTH.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de ANTH en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Paul F. Truex
CEO
Paul F. Truex serves as the Chief Executive Officer of Anthera Pharmaceuticals, Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on corporate strategy, business development, and commercialization. He has held leadership positions at various companies, contributing to the development and launch of several successful pharmaceutical products. His expertise spans across multiple therapeutic areas, including gastroenterology and immunology. Truex's experience also includes roles in finance and operations, providing a well-rounded perspective on the biopharmaceutical business.
Historial: Under Paul F. Truex's leadership, Anthera Pharmaceuticals has focused on advancing its clinical pipeline, particularly Sollpura and Blisibimod. He has overseen the progression of these drug candidates through clinical trials and has secured strategic partnerships to support their development. Key milestones include the initiation and ongoing execution of Phase III trials for Sollpura and Phase II trials for Blisibimod. His tenure has been marked by efforts to navigate the challenging regulatory landscape and secure funding for the company's research and development programs.
Información del mercado OTC de ANTH
The OTC Other tier represents the lowest tier of the OTC market, indicating that Anthera Pharmaceuticals, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information, price volatility, and illiquidity. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation and pump-and-dump schemes.
- Higher risk of fraud and mismanagement.
- Limited liquidity and wider bid-ask spreads.
- Lack of regulatory oversight and investor protection.
- Verify the company's legal status and registration.
- Review the company's financial statements, if available.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Consult with a financial advisor and conduct thorough research.
- Understand the risks associated with investing in OTC stocks.
- Established partnerships with reputable pharmaceutical companies (Amgen, Eli Lilly).
- Advancement of drug candidates through clinical trials (Phase III for Sollpura, Phase II for Blisibimod).
- Focus on addressing unmet medical needs in specific therapeutic areas.
- Experienced management team with a background in the pharmaceutical industry.
Lo Que los Inversores Preguntan Sobre Anthera Pharmaceuticals, Inc. (ANTH)
¿Cuáles son los factores clave para evaluar ANTH?
Anthera Pharmaceuticals, Inc. (ANTH) actualmente tiene una puntuación IA de 41/100, indicando puntuación baja. Fortaleza clave: Innovative pipeline of drug candidates targeting unmet medical needs.. Riesgo principal a monitorear: Potential: Failure of clinical trials for Sollpura or Blisibimod.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de ANTH?
ANTH actualmente puntúa 41/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de ANTH?
Los precios de ANTH se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre ANTH?
La cobertura de analistas para ANTH incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en ANTH?
Las categorías de riesgo para ANTH incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Failure of clinical trials for Sollpura or Blisibimod.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de ANTH?
La relación P/E para ANTH compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está ANTH sobrevalorada o infravalorada?
Determinar si Anthera Pharmaceuticals, Inc. (ANTH) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de ANTH?
Anthera Pharmaceuticals, Inc. (ANTH) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data as of March 15, 2026.
- OTC market data may be limited and less reliable than major exchange data.
- Clinical trial outcomes are inherently uncertain and can significantly impact the company's value.